Innate Pharma S.A.

Hello, everyone. Thank you for joining us and welcome to the Innate Pharma first half 2026 business update and financial results. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star 1 again. I will now hand the conference over to Stephanie Cornen, Vice President, Investor Relations, Communication and Commercial. Stephanie, please go ahead.

Good morning and good afternoon, everyone. Thank you for joining us for Innate Pharma's first half of 2026. Business Update and Financial Results Conference Call. The press release and today's presentation are both available on the IR section of our website. Before we begin, I would like to remind everyone that today's presentation includes forward-looking statements based on current expectations. These statements involve risks and uncertainties that could cause actual results to differ materially. To briefly cover today's agenda, our CEO, Jonathan Dickinson, will begin with a strategic overview and outlook. Marcus Jensen, our chief medical officer, and Yannis Morel, our chief operating officer, will then take us through updates on Lactamab, IPH4502, Monalizumab, and our preclinical ADC pipeline. Frederic Lombard, our chief financial officer, will then review our financial results. Jonathan will return for our upcoming catalysts and closing remarks before we open the call for Q&A. With that, I will now hand it over to Jonathan.

Thank you, Stephanie. Good morning to those joining from the US and good afternoon to our European participants. Turning to slide five, the first half of 2026, together with development since the end of the period, has been marked by important progress across our focus portfolio. Starting with Lecutamab, in August, we announced our strategic partnership with Sobi to advance the program in T-cell lymphoma. As announced yesterday, that partnership is now effective following the closing of the deal. And the Telemach 3, phase 3 has been initiated. We are targeting the first patient in the study in Q1 2027 as we work toward a filing for accelerated approval in cesarean syndrome in H2 2027. For IPH 4502, as announced in July, we completed phase one dose escalation and cohort enrichment enrollment and have seen preliminary anti-tumor activity, including objective responses in post-EV urophilic cancer, as well as in non-small cell lung cancer and head and neck cancer, with a favorable safety profile observed to date. We will share initial phase one dose escalation data at the EORTC NCI AACR meeting on November 18th, 2026 in Barcelona. Turning to monolizumab, enrollment in the Pacific Nine phase three study has been completed, and we continue to expect the phase three readout in the second half of 2026. Financially, our position has been strengthened by the 75 million SOBI upfront payment associated with the closing of the deal. and the 30 million equity financial. Together, these are expected to extend our projected cash runway through the end of the first quarter of 2028. Taken together, we believe these developments position innate for several important catalysts in the second half of 2026. Let me start with Lakutamab. Lakutamab is our anti-CUR3DL2 antibody being developed in cutaneous T-cell lymphoma, or CTCL. Turning to slide seven, as I mentioned, in August, we announced a strategic partnership with SOBI to license lacutimab in T-cell lymphoma. The transaction has now closed. TELEMAC3, our confirmatory phase three study in CTCL, has been initiated. with the first patient expected in the first quarter of 2027. Innate will conduct the phase three study and we will file for accelerated approval in cesarean syndrome based on the existing phase two Telemach data. Upon the potential accelerated approval, SOBI will receive exclusive global rights to commercialize lacutamab. Following positive phase three results, Sobe will be eligible to obtain full global development rights. Under the terms of the agreement, the transaction includes a 75 million upfront payment, up to 40 million in near-term milestones connected to cesarean syndrome, and up to an additional 465 million related to Sobe's options to obtain full development rights and future regulatory and commercial milestones. The agreement also includes tiered double-digit royalties on future net sales. I'll now hand it over to Markus to review the regulatory and development path forward. Markus.